Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization
- PMID: 3357892
- PMCID: PMC280090
- DOI: 10.1073/pnas.85.8.2815
Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization
Abstract
The human immunodeficiency virus (HIV) type 1 displays a high degree of genetic variation, especially in the glycoprotein (gp120) domain of the envelope gene. To determine whether this genomic heterogeneity leads to the expression of independent HIV subtypes, 12 sera from HIV type 1 antibody-positive individuals were tested for their ability to neutralize 20 HIV isolates of various origins. Four distinct HIV subtypes with different sensitivity to serum neutralization were identified. These results suggest that a finite number of HIV subtypes exist and that the combined use of selected HIV isolates representing several subtypes may be necessary for the development of an effective vaccine.
Similar articles
-
Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.Science. 1988 Feb 26;239(4843):1021-3. doi: 10.1126/science.2830667. Science. 1988. PMID: 2830667
-
Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.Viral Immunol. 1996;9(3):175-85. doi: 10.1089/vim.1996.9.175. Viral Immunol. 1996. PMID: 8890476
-
Characterization of the serological cross-reactivity between glycoproteins of the human immunodeficiency virus and equine infectious anaemia virus.J Gen Virol. 1988 Jul;69 ( Pt 7):1711-7. doi: 10.1099/0022-1317-69-7-1711. J Gen Virol. 1988. PMID: 2839603
-
Neutralizing monoclonal antibody against a external envelope glycoprotein (gp110) of SIVmac251.AIDS Res Hum Retroviruses. 1995 Apr;11(4):501-8. doi: 10.1089/aid.1995.11.501. AIDS Res Hum Retroviruses. 1995. PMID: 7632464
-
Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.Crit Rev Immunol. 1988;8(4):315-39. Crit Rev Immunol. 1988. PMID: 2850890 Review.
Cited by
-
Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.J Clin Immunol. 1992 Nov;12(6):429-39. doi: 10.1007/BF00918855. J Clin Immunol. 1992. PMID: 1287035 Clinical Trial.
-
An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.J Virol. 1998 Oct;72(10):7840-5. doi: 10.1128/JVI.72.10.7840-7845.1998. J Virol. 1998. PMID: 9733820 Free PMC article.
-
V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.J Virol. 2000 Aug;74(15):6769-76. doi: 10.1128/jvi.74.15.6769-6776.2000. J Virol. 2000. PMID: 10888615 Free PMC article.
-
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?Nat Med. 2009 Aug;15(8):866-70. doi: 10.1038/nm.1949. Nat Med. 2009. PMID: 19525964 Review.
-
Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.J Virol. 1996 Sep;70(9):6136-42. doi: 10.1128/JVI.70.9.6136-6142.1996. J Virol. 1996. PMID: 8709238 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases